Olmedo-Ocampo R, Guido-Guerra RE

Language: Spanish
References: 12
Page: 191-193
PDF size: 160.58 Kb.

ABSTRACT

The kidney metabolizes and clears multiple drugs from the organism. Therefore, in order to choose which medication to use in this population, the glomerular filtration rate (GFR), risk of acute kidney injury and potential pharmacologic interactions must be considered. Since NSAIDs and some opioids use is limited in patients with decreased GFR, the analgesic strategy employed should prioritize neuroaxial or regional blockade, multimodal analgesia and the use of adjuvants with dose adjustments.

REFERENCES

1. Tawfic Q, Bellingham G. Postoperative pain management in patients with chronic kidney disease. Journal of Anaesthesiology Clinical Pharmacology. 2015;31:6.

2. Summary of Recommendation Statements. Kidney International Supplements. 2013;3:5-14.

3. Summary of Recommendation Statements. Kidney International Supplements. 2012;2:8-12.

4. Ungprasert P, Cheungpasitporn W, Crowson C, Matteson E. Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis of observational studies. European Journal of Internal Medicine. 2015;26:285-291.

5. Bell S, Rennie T, Marwick CA, Davey P. Effects of peri‐operative nonsteroidal anti‐inflammatory drugs on post‐operative kidney function for adults with normal kidney function. Cochrane Database of Systematic Reviews. 2018;11.

6. Solomon D, Husni M, Libby P, Yeomans N, Lincoff A, Lüscher T, et al. The risk of major NSAID toxicity with celecoxib, ibuprofen, or naproxen: a secondary analysis of the PRECISION trial. The American Journal of Medicine. 2017;130:1415-1422.e4.

7. Koncicki HM, Unruh M, Schell JO. In practice pain management in CKD: a Guide for Nephrology Providers. Am J Kidney Dis. 2016. doi: 10.1053/j.ajkd.2016.08.039.

8. Barakzoy A, Moss A. Efficacy of the World Health Organization analgesic ladder to treat pain in end-stage renal disease. Journal of the American Society of Nephrology. 2006;17:3198-3203.

9. Davison S, Koncicki H, Brennan F. Pain in chronic kidney disease: a scoping review. Seminars in Dialysis. 2014;27:188-204.

10. Raouf M, Atkinson T, Crumb M, Fudin J. Rational dosing of gabapentin and pregabalin in chronic kidney disease. Journal of Pain Research. 2017;10:275-278.

11. Schug SA, Palmer GM, Scott DA, Halliwell R, Trinca J. Acute pain management: scientific evidence, 2015. Medical Journal of Australia. 2016;204:315-317.

12. Ishida JH, McCulloch CE, Steinman MA, Grimes BA, Johansen KL. Gabapentin and pregabalin use and association with adverse outcomes among hemodialysis patients. J Am Soc Nephrol. 2018;29:1970-1978.